SCHEDULE: Glazer Capital Discloses 6.61% Stake in Astria Therapeutics

Glazer Capital, LLC and Paul J. Glazer have reported a 6.61% beneficial ownership stake in Astria Therapeutics, Inc. as of December 31, 2025.

Summary

• Glazer Capital, LLC and Paul J. Glazer collectively hold 3,776,154 shares of Astria Therapeutics, Inc. common stock.
• This ownership represents 6.61% of Astria Therapeutics' outstanding common stock.
• The shares are held by various funds and managed accounts for which Glazer Capital serves as the investment manager.
• Paul J. Glazer, as the Managing Member of Glazer Capital, is also a reporting person.
• The reporting persons share both voting and dispositive power over all 3,776,154 shares.
• The securities were not acquired for the purpose of changing or influencing control of Astria Therapeutics, except for activities solely in connection with a nomination under Rule 240.14a-11.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive development, as a substantial institutional investment often reflects confidence in the company's long-term potential. However, the explicit mention of potential director nominations introduces an element of potential future governance challenges or strategic shifts.

Positives

• A significant institutional investor, Glazer Capital, has taken a substantial 6.61% stake in Astria Therapeutics, indicating potential confidence in the company's future prospects.
• The filing explicitly states the securities were not acquired for the purpose of changing or influencing control, which can reassure current management and reduce immediate activist concerns, though the 'nomination' clause adds a nuance.

Negatives

• The inclusion of 'other than activities solely in connection with a nomination under ?? 240.14a-11' suggests a potential for future engagement in director nominations, which could lead to governance challenges or proxy contests.

Risks

• Potential for future shareholder activism: The statement regarding activities solely in connection with a nomination under Rule 240.14a-11 indicates that Glazer Capital may seek to nominate directors to Astria Therapeutics' board, which could lead to a proxy contest or influence management decisions.
• Market perception risk: The disclosure of a significant stake by an activist-leaning fund could lead to speculation about the company's strategic direction or management stability.

Industry Context

StockSavvy.ai notes that a significant stake by an investment firm like Glazer Capital in a biotechnology company such as Astria Therapeutics often signals an expectation of future value creation, potentially through strategic changes, operational improvements, or a belief in the underlying drug pipeline. Such disclosures can sometimes precede increased market scrutiny or activist engagement, especially given the specific language regarding director nominations.

Stakeholder Impact

• Shareholders: May see increased confidence due to institutional investment, but also potential for future activist pressure or strategic changes.
• Management: Could face increased scrutiny or engagement from a significant shareholder, potentially leading to board nominations.

Key Dates

Recommendation

The disclosure of a significant 6.61% stake by Glazer Capital in Astria Therapeutics is a notable event. While it signals institutional interest and potential belief in the company's value, the explicit mention of potential director nominations under Rule 240.14a-11 suggests a possible activist stance. This introduces an element of uncertainty regarding future corporate governance and strategic direction. Investors should hold to observe how this relationship develops and what, if any, actions Glazer Capital takes regarding board nominations or strategic influence before making further investment decisions.

Keywords

Astria Therapeutics, Glazer Capital, Paul J. Glazer, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investor, Shareholder Activism, Biotechnology, Pharmaceuticals